Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT01605721

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01605721
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01605721. Allocation not applicable; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
Intervention (Device)
XIENCE PRIMETM everolimus-eluting coronary stent
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Abbott (class: industry)

Record details

Record id
cardio:ct-nct01605721
Content hash
873faa4e4705405de6aba3570f4b427f8dac182a018a1b9a58332b396ab41b69